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Objective: In January 2008, the Food and Drug Administration (FDA) communicated concerns and, in May 2009,
issued a warning about an increased risk of suicidality for all antiepileptic drugs (AEDs). This research evaluated
the association between the FDA suicidality communications and the AED prescription claims among members
with epilepsy and/or psychiatric disorder.
Methods: A longitudinal interrupted time-series design was utilized to evaluate Oklahoma Medicaid claims data
from January 2006 through December 2009. The study included 9289 continuously eligible members with prev-
alent diagnoses of epilepsy and/or psychiatric disorder and at least oneAEDprescription claim. Trends, expressed
asmonthly changes in the log odds of AED prescription claims, were compared across three time periods: before
(January 2006 to January 2008), during (February 2008 to May 2009), and after (June 2009 to December 2009)
the FDA warning.
Results: Before the FDAwarning period, a signiﬁcant upward trend of AEDprescription claims of 0.01% permonth
(99% CI: 0.008% to 0.013%, p b 0.0001) was estimated. In comparison to the prewarning period, no signiﬁcant
change in trend was detected during (−20.0%, 99% CI: −70.0% to 30.0%, p = 0.34) or after (80.0%, 99% CI:
−20.0% to 200.0%, p = 0.03) the FDA warning period. After stratiﬁcation, no diagnostic group (i.e., epilepsy
alone, epilepsy and comorbid psychiatric disorder, and psychiatric disorder alone) experienced a signiﬁcant
change in trend during the entire study period (p N 0.01).
Conclusions:During the time period considered, the FDAAED-related suicidalitywarning does not appear to have
signiﬁcantly affected prescription claims of AED medications for the study population.© 2014 Elsevier Inc. All rights reserved.1. Introduction
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cians, as well as by several professional organizations, speciﬁcally
the American Epilepsy Society (AES) [3]. Some independent investiga-
tors questioned the validity of the FDA ﬁndings after identifying serious
methodological ﬂaws [4,5]. Since the release of the warning, a number
of observational studies have investigated the association between
AEDs and suicidality [6–11]. These results have been conﬂicting with
some studies reporting an increased risk of suicidality [6–9] while
others reporting no increased risk [10,11].
The FDA communication and conﬂicting evidence available may
complicate the decision to prescribe AEDs. Shneker et al. [12] surveyed
175 neurologists, and 46% of practitioners reported no change in clinical
practice because of the FDA alert. However, the study response ratewas
only 22%, and the results may not be representative of all neurologists
and/or prescribers of AEDs.
This study further attempts to quantify and evaluate the associa-
tion between dissemination of the FDA suicidality warning and AED
prescription claims among Oklahoma Medicaid members diagnosed
with epilepsy and/or psychiatric disorder(s) from January 2006 through
December 2009.
2. Material and methods
2.1. Study design
A longitudinal interrupted time-series analysis of Oklahoma Medic-
aid claims data from January 2006 through December 2009 was used
to evaluate the change in AED prescription claims before and after the
FDA suicidality alert and warning. A time series of 48 consecutive
monthswas created using person-month level data as a unit of analysis.
For each month, the proportion of members with an AED prescription
claim was calculated.
Two interruptionswere introduced during the studyperiod. Theﬁrst
interruption was the month (January 2008) when the FDA alert was is-
sued. The second interruption was the month (May 2009) when the
FDA warning was issued. These two interruptions created 3 time seg-
ments with 2 change points in a time series of 48 months. TheMedicaidFig. 1. Inclusion and exclusion critadministrative data comprised the analytical ﬁle for a time series of var-
iables with aggregated values spanning 25 months before, 16 months
during, and 7 months after the FDA warning. This study was reviewed
and approved by the IRB at the University of Oklahoma.
2.2. Study population
A historical cohort was selected from the Oklahoma Medicaid ad-
ministrative claims data which include eligibility, medical, and pharma-
cy claims ﬁles. All three ﬁles included data elements to identify unique
members to permit matching records across the ﬁles.
Fig. 1 depicts the member inclusion and exclusion process. There
were 1,183,668 members enrolled in the Oklahoma Medicaid program
between January 2006 and December 2009. A group of 14,881 continu-
ously eligible members was selected who were less than 65 years of
age, were not dually-eligible for Medicaid and Medicare, had at least
onemedical claimwith a diagnosis of epilepsy and/or psychiatric disor-
der(s) in an inpatient or outpatient setting, and had at least one AED
prescription claim between January 2006 and December 2009 (Table 1).
The date of the ﬁrst AED prescription claim during the study period
was considered the AED prescription index date. Lacosamide (October
2008) and ruﬁnamide (November 2008) were new branded drugs
launched during the study period and excluded from the study since
they involved only 29 individuals. Members were excluded if they had
received a diagnosis of attempted suicide (ICD-9-CM: E950–E959) on
or six months prior to the AED prescription index date or received
polytherapy (2 or more AED drugs, more severely ill group) within
the time period of when the days' supply of ﬁrst AED claim had not
been exhausted. Memberswith less than 15 days of AED therapy during
the entire study period were also excluded, leaving the study popula-
tion of 12,841 members.
After potential study members were identiﬁed, the period between
July 1, 2005 and December 31, 2005 served as a prescreening period
to identify prevalent (existing) members of epilepsy and/or psychi-
atric disorder with a diagnosis on or prior to the beginning of the
study, January 2006. Subsequently, only 9289 members with existing
diagnoses of epilepsy and/or psychiatric disorder were selected for theeria for the study population.
Table 1
A list of diagnostic groups as indicated by the International Classiﬁcation of Diseases, 9th
Revision, Clinical Modiﬁcation (ICD-9-CM) codes and a list of antiepileptic drugs (AEDs)
included in the study.
Factors Categories (ICD-9)
I. Diagnoses
(a) Epilepsy alone [16] Epilepsy (345.xx)
Convulsion (780.3x)
(b) Psychiatric disorder
alone
Psychiatry disorder (295–319)
– Depression (296.2x, 296.3x, 300.4, 311)
– Bipolar disorder (296.0x, 296.1x, 296.4x–296.8x)
– Schizophrenia (295.xx)
– Anxiety/phobia disorder (300.0x, 300.2x, 300.3)
– Adjustment disorder (309.xx)
– ADHD (314.0x)
– Other psychiatric disorder
(c) Epilepsy and
comorbid psychiatric
disorder
Patients diagnosed with both medical conditions
II. Antiepileptic drugs
(AEDs)
Carbamazepine, clonazepam, clorazepam,
divalproex sodium, valproic acid, ethosuximide,
ethotoin, mephenytoin, methsuximide, phenytoin,
primidone, lamotrigine, gabapentin, pregabalin,
oxcarbazepine, levetiracetam, tiagabine, topiramate,
vigabatrin, felbamate, zonisamide
111M. Mittal et al. / Epilepsy & Behavior 34 (2014) 109–115ﬁnal study population in order to ensure a standardized length of expo-
sure time and to reduce bias related to the time-varying nature of an
AED prescription ﬁll (Fig. 1).
2.3. Study variables
2.3.1. Dependent variable
The ﬁlling of an AED prescription claim for at least 15 days at each
monthly time point was calculated in the study population. For each
member, a supply diary of AED was created by adding together consec-
utive ﬁlling of AED based on ﬁlling dates and the reported days supply
[13]. The days supply of a prescription claim could vary from one to
three months. The days supply information available from the pharma-
cy claims was utilized for calculating the proportion of days supply of
AEDduring a givenmonth for each studymember. Additionally, amem-
ber could reﬁll their AEDmedication before exhausting the previous ﬁll,
creating overlapping days supply [13]. In this case, the proportion of
days supplied was calculated in the same manner and “credited” the
member with ﬁnishing the previous ﬁll [13]. For example, if a member
ﬁlled an AED prescription claim for a 30-day supply on 1/1/07 and
reﬁlled the next prescription on 1/23/07, then that member was
credited with 7 more days supply, and days supply of reﬁlled claim
was started over on 1/30/07.Memberswith at least 15days of AED ther-
apywere considered studymemberswith anAED prescription claim for
that month.
2.3.2. Independent variable
The study period of 48 months from January 2006 to December
2009 served as the independent variable. While this study focused pri-
marily on the periods immediately before and after the introduction of
the FDA warning, the study months were divided into 3 distinct time
periods: (1) before the FDA warning (January 2006 to January 2008),
(2) during the FDA warning (February 2008 to May 2009), and
(3) after the FDA warning (June 2009 to December 2009) to more ex-
plicitly account for a potential lag period between the implementation
of the FDA warning and the prescribing physicians' response to it.
2.3.3. Covariates
The selection of covariates was guided by the Andersen Behavioral
Model for Access to Medical Care and included predisposing (i.e., in-
dividuals' propensity to use services), need (i.e., illness level), and en-
abling (i.e., individuals' ability to access services) factors that havebeen identiﬁed to potentially inﬂuence the use of health services [14].
Predisposing characteristics included age group, sex, and race. Need
characteristics included diagnostic groups [15], neurological comorbid-
ities [2,16–18], other comorbid conditions [19,20], and use of psycho-
tropic drugs. Diagnostic groups comprised of members diagnosed with
epilepsy alone, epilepsy and comorbid psychiatric disorder, and psychi-
atric disorder alone during the study period [15]. An indicator variable
of neurological comorbidities was created from a list of four chronic
conditions (i.e., neuropathic pain, migraine, movement disorder, or
chronic pain) commonly treated with AEDs [2,16–18]. Other comorbid
conditions were adjusted by estimating the Charlson comorbidity
index indicating the severity of the disease and categorized into 0 or
≥1 comorbid score [19,20]. Use of psychotropic drugs indicatedwheth-
er or not psychotropic therapy (i.e., antidepressant, antipsychotic, stim-
ulants, or anxiolytic/hypnotic agents) was received on or prior to
the AED prescription index date. Enabling characteristics included
physician's specialty, geographical region, and metropolitan statistical
area (MSA) status. Physicians' specialty indicatedwhether or not a phy-
sician was a central nervous system (CNS)-related health-care provider
who had prescribed the ﬁrst AED prescription to an individual (Table 2).
2.4. Statistical analysis
Univariate and descriptive statistics were used to proﬁle all study
covariates. Because of the binomial distribution of the outcome, a linear
regression line was ﬁt on a log odds (logit) scale. Segmented logistic
regression models [21] using generalized estimation equations (GEE)
were employed to estimate change in level (intercept) and trend
(slope) in AED prescription claims during and after the FDA warning
with the prewarning period as the referent. The model was adjusted
for each of the predisposing, enabling, and need characteristics. Auto-
correlation between repeated observations was detected using
correlograms (i.e., residuals versus time) [22] and the Durbin–Watson
test statistics [23] and subsequently adjusted by assuming a ﬁrst-order
autoregressive [AR (1)] covariance structure. Data management and
analysis were accomplished via PC-SAS (v 9.2), with an a priori alpha
set at 0.01 to determine statistical signiﬁcance.
3. Results
The ﬁnal study population consisted of 9289 continuously eligible
memberswith prevalent diagnoses of epilepsy and/or psychiatric disor-
derwhohad ﬁlled anAED prescription claim between January 2006 and
December 2009. Baseline predisposing, enabling, and need characteris-
tics of the study population are presented in Table 2. The study popula-
tion involved members who were largely children b18 years of age
(39.5%), female (56.1%), and white (75.3%). The majority of the study
members were diagnosed with psychiatric disorder(s) (62.3%), follow-
ed by members with epilepsy diagnoses and comorbid psychiatric dis-
order(s) (34.0%) and (3.7%) members with epilepsy alone.
In the overall study population, the percentage of study members
with an AED prescription claim slowly but consistently increased,
from 38.36% to 46.90%, between January 2006 and December 2009.
Fig. 2 depicts the pattern of AED prescription claims for each diagnostic
group throughout the study period. For the group ofmemberswith a di-
agnosis of epilepsy alone, the percentage of studymemberswith anAED
prescription claim declined over time from 72.17% to 58.55%. However,
this pattern steadily increased in members with diagnoses of epilepsy
and comorbid psychiatric disorder(s) trending upward from 53.42% to
63.47% and in members with psychiatric disorder(s) alone trending
from 28.10% to 37.15%.
The association between the FDA suicidalitywarning and the antiep-
ileptic drug prescription claims was quantiﬁed and reported using
the prewarning period as a referent group (Table 3). Before the FDA
warning period, a statistically signiﬁcant upward trend (slope) of
AED prescription claims of 0.01% per month (99% CI: 0.008% to 0.013%,
Table 2
Descriptive analysis: Predisposing, enabling, and need characteristics of the study
population from January 2006 through December 2009 (N = 9289).
Characteristics Study population,
N = 9289 (%)
Predisposing characteristics
Age
b18 3671 (39.5%)
18–44 2936 (31.6%)
45–64 2682 (28.9%)
Sex
Female 5212 (56.1%)
Male 4077 (43.9%)
Race
White 6991 (75.3%)
Black 1209 (13.0%)
Othera 1089 (11.7%)
Need characteristics
Diagnostic groups
Epilepsy alone 345 (3.7%)
Epilepsy and comorbid psychiatric disorder 3162 (34.0%)
Psychiatric disorder alone 5782 (62.3%)
Neurological comorbiditiesb (neuropathic pain,
migraine, movement disorder, or chronic pain)
Yes 3799 (40.9%)
No 5490 (59.1%)
Other comorbiditiesc (Charlson comorbidity index)
0 3325 (35.8%)
≥1 5964 (64.2%)
Use of psychotropic therapy (antidepressant,
antipsychotic, stimulants, anxiolytic/hypnotics)
Yes 7125 (76.7%)
No 2164 (23.3%)
Enabling characteristics
CNS health-care providerd
Yes 3026 (32.6%)
No 6263 (67.4%)
G. region
NW 598 (6.4%)
SW 905 (9.7%)
OKC 2621 (28.2%)
Tulsa 1779 (19.2%)
NE 1574 (16.9%)
SE 1742 (18.8%)
MSA
Urban 5156 (55.5%)
Rural 4004 (43.1%)
Age, sex, race, use of psychotropic therapy, physician specialty, geographical region, and
MSA were measured at the AED prescription index date. Diagnostic groups, neurological
comorbidities, and other comorbidities were measured during the entire study period.
Percentage of geographic region andMSA did not add up to 100% because ofmissing data.
a Other races included Asian, Native Hawaiian/other Paciﬁc Islander, American Indian/
Alaska Native, and multiple races.
b Neurological comorbidities included a list of four chronic conditions commonly
treated with AEDs, i.e., neuropathic pain [diabetes with neurological manifestations
(250.6x), trigeminal nerve disorders (350.xx), glossopharyngeal neuralgia (352.1x),
neuropathy (356.0x, 356.8x), postherpetic trigeminal neuralgia (053.12), and unspeciﬁed
neuralgia, neuritis, and radiculitis (729.2x)]; migraine (346.xx); movement disorder
[essential tremor (331.1x, 781.0x), restless legs syndrome (333.94)]; and chronic pain
(338.2x, 729.1x) [2,16–18].
c Other comorbid conditions were adjusted by measuring the Charlson comorbidity
index indicating the severity of the disease [19,20].
d Physicians' specialty indicated whether or not a physician was a central nervous
system (CNS) health-care provider who had prescribed theﬁrst AED prescription to an in-
dividual. A list of CNS health-care providers included psychiatric hospital, intermediate
care facility/mental health (ICF/MH) N 6 beds, intermediate care facility/mental health
(ICF/MH) b 6 beds, outpatient mental health clinic, community mental health center
(CMHC), psychologist, preadmission screening and resident review (PASRR) CMHC,
health service provider in psychology (HSPP), mental health — department of mental
health and substance abuse services (DMHSAS), mental health case management for
all ages (public and private), neurological surgeon, neurologist, psychiatrist, and child
psychiatrist.
112 M. Mittal et al. / Epilepsy & Behavior 34 (2014) 109–115p b 0.0001) was estimated. In comparison to the prewarning period, no
immediate change in AED prescription claims was detected at the time
of the FDA alert in January 2008 [change in level (y-intercept)=−6.5%,99% CI:−11.3% to 0.3%, p = 0.014]. However, members with an AED
prescription claim statistically signiﬁcantly declined at the time of the
FDA warning in May 2009 [change in level (y-intercept) = 14.5%, 99%
CI: 8.1% to 22.6%, p b 0.0001]. No signiﬁcant change in AED prescription
claim was detected during [change in trend (slope) = −20.0%, 99%
CI: −70.0 to 30.0%, p = 0.34] or after [change in trend (slope) =
80.0%, 99% CI: −20.0% to 200.0%, p = 0.03] the FDA warning period
when compared to the preperiod.
The overall study population was further stratiﬁed into three mutu-
ally exclusive diagnostic groups (epilepsy alone, epilepsy and comorbid
psychiatric disorder, and psychiatric disorder alone) to determine the
potential change in AED prescription claims due to the FDA suicidality
warning (Table 3). A signiﬁcant immediate decline in AED prescription
claims was detected among two diagnostic groups [epilepsy with co-
morbid psychiatric disorder(s) (change in level = 14.8%, 99% CI: 1.6%
to 27.9%, p = 0.005) and psychiatric disorder(s) alone (change in
level = 15.2%, 99% CI: 6.0% to 24.2%, p b 0.0001)] at the time of the
FDA warning in May 2009 when compared to the prewarning period.
Similar to the overall study population, no signiﬁcant change in trend
(slope) of AED prescription claims was detected in all three diagnostic
groups during the entire study period (p N 0.01).
4. Discussion
Among our study members, there was a signiﬁcant increase in the
trend of AED prescription claims in the prewarning period. Although
the FDA suicidality warning issued in May 2009 appeared to have a
small, immediate impact on AED prescription claims, no signiﬁcant
change in trend was detected across any segment of the study period.
This ﬁnding suggests that the FDA suicidality warning had partially
“reset” the prescribing pattern to a lower level; however, over time
and with experience, physicians may have assessed the risk to beneﬁt
of treatmentwith an AED or were unaware of the FDA risk communica-
tion [24,25].
According to Bell et al. [25] an online survey of the American Acade-
my of Neurology (AAN) members showed that roughly 20% of health-
care professionals caring for patients with epilepsy were not aware of
major FDA drug safety warnings including suicidality warning for anti-
epileptic medicines. Of those who were aware of the safety alerts, as
few as 23% said that they remembered speciﬁc knowledge of the risks
presented in a given alert. The current study supports the results of
Bell et al. [25] by detecting no signiﬁcant association between the FDA
suicidality warning and the trend of AED prescription claims using
Medicaid administrative data. Along with lack of awareness in health-
care professionals about the FDA risk communication, there are social
and psychological factors (i.e., lack of media coverage and stigma asso-
ciated with epilepsy) that may result in no change in AED prescription
claims over time [26,27].
It is important to note that AEDs are prescribed for several other
indications that are unrelated to epilepsy or psychiatric disorder.
This study focused on the evaluation of the impact of the FDA suicidality
warning on diagnoses of epilepsy and/or psychiatric disorder because
themajority of OklahomaMedicaid members (92%) receiving AED pre-
scription claims were diagnosed with epilepsy and/or psychiatric dis-
order. In concordance with prior research [28,29], this study also
determined that the majority (62.3%) of these members received an
AED for a diagnosis of psychiatric disorder alone. This result is especially
interesting since most AEDs prescribed for psychiatric conditions are
prescribed without an FDA-approved indication [28].
For the epilepsy alone diagnostic group, the pattern of AED prescrip-
tion claims appears to decline over time (Fig. 2). This is somewhat sur-
prising because there is no alternative pharmacotherapy available for
the treatment of epilepsy. Moreover, not treating patients with epilepsy
may bemore harmful than treating themwith AEDs [30]. One potential
reason for this unexpected pattern is that approximately 25% (85 out of
345) of members with epilepsy alone were less severely ill with a
Fig. 2. Patterns of AED prescription claims in a study population diagnosedwith epilepsy alone (n= 345), epilepsy and comorbid psychiatric disorder (n= 3162), or psychiatric disorder
alone (n = 5782) plotted on 48-month time series from January 2006 through December 2009.
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tientswith epilepsy (ICD-9-CM: 345.xx). Providersmay have decided to
stop prescribing AEDs over time in these members based on a cautious
watchful-waiting and intermittent risk–beneﬁt review [31].
Members with epilepsy and comorbid psychiatric disorder(s) may
represent amore severely affected group of patients in terms of medical
illness since comorbid psychiatric disorder has been reported as an in-
dependent risk factor for a decreased quality of life as well as increased
mortality in patients with epilepsy [32–34]. Because of the potential to
havemembers with more severe disease, the percentage with AED pre-
scription claims in this diagnostic group appears to increase consistently
over time (Fig. 2).
On average, the percentage of members with AED prescription
claims was relatively low compared to the other two diagnostic groups
for the psychiatric disorder alone diagnostic group (Fig. 2). This ﬁnding
was expected because several AEDs are not FDA-approved for psychiat-
ric conditions and are associated with off-label use [16,28,35]. Despite
the potential off-label use, the percentage of members with AED pre-
scription claims does increase over time.
This study has several strengths that must be considered. This is the
ﬁrst study to examine the association between the FDA AED warning
and the AED prescription claims using real-world administrative data.
Previously, only one study was conducted where Shneker et al. [12]
surveyed neurologists to determine the impact of the FDA suicidality
alert on their attitude and behavior when prescribing AEDs. The author
reported a low impact of the FDA alert on clinical practice. The current
study supports the Shneker et al. [12] ﬁndings by examining a large
historical Medicaid administrative dataset with a rigorous analytical ap-
proach. The longitudinal feature of the administrative data strengthens
the ability to determine temporal relationships between predictor and
outcome variables. Finally, the use of a GEE estimation technique is a
major advantage because it uses individual-level data and enables
modeling the impact of thewarning onAEDprescription claims after ac-
counting for individual characteristics [36]. Additionally, this technique
accounts for the within subject autocorrelation by incorporating a
working covariance matrix [36]. In contrast, previous studies related
to other FDA risk communications have used the aggregated time-
series design wherein data are collapsed across individuals to create a
time series [37,38].
This study has important limitations to consider. The AED-related
suicidality issue was ﬁrst raised in 2004, but reliable administrative
claims data were not available before January 1, 2006 in the OklahomaMedicaid dataset. The time period included after the FDA warning was
very short, potentially too short to measure a potential long-term
change in outcomemeasures. Theremay be several other factors includ-
ing advertising by pharmaceutical manufacturers, competing commu-
nications by professional organizations, publication of new safety and
effectiveness information, and media reports that could affect the utili-
zation pattern of AEDs during that period. These external factors could
not be accounted for in this study. The design of this study did not
allow for the examination of utilization patterns of speciﬁc AEDs in pa-
tients with epilepsy and/or psychiatric disorder because certain AEDs
(i.e., gabapentin) are widely used off-label in diabetic neuropathy, mi-
graine, or chronic pain [28]. These indicationsmay not be representative
in the study population and produce biased results for speciﬁc AEDs
used. This studydid not includememberswith incident diagnoses of ep-
ilepsy or psychiatric disorder in the analytical sample because of limited
sample size. Exclusion ofmembers taking polytherapy (2 ormore AEDs,
more severely ill group) at the AEDprescription index date limits gener-
alizability of these results to those receiving monotherapy at baseline.
Missing data are always a potential problem, especially in research
employing claims data. Because of missing data on individual physician
specialty, all CNS health-care providers were collapsed into one catego-
ry, and we could not assess the impact of the warning within CNS
health-care providers. Finally, Medicaid claims data employed in this
research came from a single state, which may limit generalizability of
results.
5. Conclusions
The FDA suicidality warning issued in May 2009 appeared to have a
small immediate impact on AED prescription claims, but no signiﬁcant
changes in trend were detected throughout the study period. Also, the
FDAAED-related suicidalitywarningdoes not appear to have inﬂuenced
AED prescription claims across diagnostic groups. Future research is re-
quired to examine the impact of the FDA suicidality warning on the uti-
lization pattern of speciﬁc AEDs.
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Table 3
Segmented regression model: Point estimates with 99% CI, % change in log odds of AED Rx claims with 99% CI, and p-value among the study population in the Oklahoma Medicaid setting from January 2006 through December 2009.
Level/trend Epilepsy and/or psychiatric disorder(s)
(N = 9289)
Epilepsy alone
(n = 345)
Epilepsy + comorbid psychiatric
disorder(s)
(n = 3162)
Psychiatric disorder(s) alone
(n = 5782)
Point estimates
(99% CI)
Change in log odds
of AED Rx claims %
(99% CI)†
Point estimates
(99% CI)
Change in log odds
of AED Rx claims %
(99% CI)†
Point estimates
(99% CI)
Change in log odds
of AED Rx claims %
(99% CI)†
Point estimates
(99% CI)
Change in log odds
of AED Rx claims %
(99% CI)†
Baseline level (β0) 0.62⁎⁎
(0.39 to 0.84)
Referent 1.08⁎⁎
(0.52 to 1.65)
Referent 0.61⁎⁎
(0.42 to 0.81)
Referent −0.66⁎⁎
(−0.86 to−0.47)
Referent
Baseline trend (β1) 0.01⁎⁎
(0.008 to 0.013)
Referent −0.01
(−0.03 to 0.001)
Referent 0.013⁎⁎
(0.01 to 0.02)
Referent 0.01⁎⁎
(0.006 to 0.013)
Referent
Level change at FDA alert (β2) −0.04
(−0.07 to 0.002)
−6.5%
(−11.3 to 0.3)
−0.06
(−0.26 to 0.14)
−5.5%
(−24.1 to 13.0)
−0.06
(−0.13 to 0.002)
−9.8%
(−21.3 to 0.3)
−0.02
(−0.07 to 0.03)
−3.0%
(−10.6 to 4.5)
Trend change during FDA warning (β3) −0.002
(−0.007 to 0.003)
−20.0%
(−70.0 to 30.0)
0.002
(−0.02 to 0.03)
20.0%
(−200.0 to 300.0)
−0.005
(−0.013 to 0.003)
−38.5%
(−100.0 to 23.0)
−0.0003
(−0.01 to 0.01)
−3.0%
(−100.0 to 100.0)
Level change at FDA warning (β4) −0.09⁎⁎
(−0.14 to−0.05)
−14.5%
(−22.6 to−8.1)
−0.09
(−0.31 to 0.13)
−8.3%
(−28.7 to 12.0)
−0.09⁎
(−0.17 to−0.01)
−14.8%
(−27.9 to−1.6)
−0.1⁎⁎
(−0.16 to−0.04)
−15.2%
(−24.2 to−6.0)
Trend change after FDA warning (β5) 0.008
(−0.002 to 0.02)
80.0%
(−20.0 to 200.0)
0.009
(−0.03 to 0.05)
90.0%
(−300.0 to 500.0)
0.002
(−0.02 to 0.02)
15.4%
(−153.8 to 153.8)
0.01
(−0.001 to 0.025)
100.0%
(−10.0 to 250.0)
The models were estimated using PROC GENMOD (SAS 9.2) with a binomial distribution logit function. The correlation structure was AR (1). The overall model was adjusted for a number of covariates including age, sex, race, diagnostic groups,
neurological comorbidities, other comorbidities, use of psychotropic therapy, physician specialty, geographical region, and MSA. All three stratiﬁed diagnosis-speciﬁc models were adjusted for a number of covariates excluding diagnostic groups.
†Example of calculating change in log odds of AED Rx claims %.
% change in trend of AED Rx claims during the FDA warning (β3) in patients with epilepsy and/or psychiatric disorder(s) (N = 9289) = trend change during the FDA warning period / baseline trend in prewarning period = β3 ∗ 100 /
β1 = 0.002 ∗ 100 / 0.01 = 20.0%.
Calculation of 99% CI: (a) lower bound = 0.007 ∗ 100 / 0.01 = 70.0%; (b) upper bound = 0.003 ∗ 100 / 0.01 = 30.0%.
% change in log odds of AED Rx claims during the FDAwarning periodwas−20.0% (99% CI:−70.0 to 30.0). Other calculationswere performed in a similarmanner. Negative sign indicates the decline in log odds of AED Rx claims andwas not included
in the mathematical calculation.
⁎ p b 0.01.
⁎⁎ p b 0.0001.
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